Eli Lilly and Company and Innovent Biologics, Inc.
Type: License agreement
In-Licensee: Eli Lilly and Company
Out-Licensor: Innovent Biologics, Inc.
Focus: Novel medicines in oncology and immunology
Upfront Payment: $350 million
Milestone Payment: $8.5 billion
Financial impact: The potential ~$8.5 billion in milestone payments, along with tiered royalties on global sales, represents a transformative long-term revenue opportunity for Innovent, significantly enhancing the value of its pipeline beyond existing products and partnerships.
Innovent Biologics announced its seventh strategic collaboration with Eli Lilly and Company to advance oncology and immunology medicines, under which Innovent will lead development through Phase 2 in China while Lilly holds exclusive rights outside Greater China; Innovent will receive $350 million upfront, up to ~$8.5 billion in potential milestones, and tiered royalties on ex-China sales.
Through the agreement, Innovent will use its antibody platforms and clinical expertise to lead development through Phase 2 in China, while Lilly gains exclusive rights to develop and commercialize the therapies outside Greater China, with Innovent retaining rights within the region.
Oncology and Immunology drugs
Over the past decade, both oncology and immunology drug markets have experienced substantial revenue growth, reflecting rising global demand for advanced therapies and expanding treatment options. Oncology drug revenues, which were reported at about $100 billion in 2015, reached $250.88 billion in 2025, driven by the widespread adoption of targeted therapies, immuno‑oncology agents, and precision medicine approaches. Similarly, the immunology drug market more than doubled over the same period, climbing from around $61.5 billion in 2015 to $117 billion in 2025, fueled by innovations in biologics and treatments for chronic autoimmune and inflammatory diseases. Looking ahead, both segments are expected to continue their upward trajectories as new scientific advancements, expanded indications, and broader global access support sustained revenue increases well beyond 2025.
Eleven years of market revenue of Oncology and Immunology drugs (2015-2025)
Fig 7: Market revenue of oncology and Immunology drugs
Eleven years' market revenue of Eli Lilly and Company
Over the past 11 years, Eli Lilly’s revenue growth has been supported in part by strong sales of oncology and immunology drugs, with its breast cancer therapy Verzenio generating over $5.3 billion in annual sales and immunology drug Taltz contributing approximately $3.3 billion in revenue, underscoring how expanding adoption of these high‑value therapies has helped diversify and strengthen Lilly’s overall financial performance alongside its broader portfolio trends.
Eleven years of market revenue of Eli Lilly and Company (2015-2025)
Fig 8: Market revenue of Eli Lilly and Company
Market Impact of This Partnership
In 2026, the strategic licensing agreement between Eli Lilly and Company and Innovent Biologics significantly impacted the market by boosting Innovent’s stock by ~6%, validating its R&D capabilities, and strengthening global positioning in oncology and immunology. The deal, which includes a $350 million upfront payment, up to $8.5 billion in milestone payments, and tiered royalties outside Greater China, provides immediate capital and substantial long-term revenue potential, while exemplifying the growing trend of cross-border collaborations between Chinese biotechs and global pharmaceutical companies.
“The Lilly–Innovent 2026 deal boosts Innovent’s global presence, investor confidence, and long-term revenue potential through a landmark cross-border collaboration.”